| 1 |
Thuss-Patience P, Stein A. Immunotherapy in squamous cellcancer of the esophagus［J］. Curr Oncol, 2022, 29（4）： 2461-2471.
|
| 2 |
Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-yearoutcome of neoadjuvant chemoradiotherapy plus surgery foresophageal cancer：the randomized controlled CROSS trial［J］. J Clin Oncol, 2021, 39（18）：1995-2004.
|
| 3 |
He J, Chen WQ, Li ZS, et al. China guideline for the screening,early detection and early treatment of esophageal cancer （2022,Beijing）［J］.Zhonghua Zhong Liu Za Zhi, 2022, 44（6）： 491-522.
|
| 4 |
Ohmori M, Ishihara R, Aoyama K, et al. Endoscopic detection anddifferentiation of esophageal lesions using a deep neural network［J］. Gastrointest Endosc, 2020, 91（2）： 301-309.
|
| 5 |
王孟.中国食管癌高发区食管癌前病变患病与进展风险预测的前瞻性队列研究［D］. 北京： 中国医学科学院北京协和医学院, 2019.
|
| 6 |
Morita FHA, Bernardo WM, Ide E, et al. Narrow band imaging versus lugol chromoendoscopy to diagnose squamous cell carcinoma of the esophagus： a systematic review and meta-analysis［J］. BMC Cancer,2017, 17（1）： 54.
|
| 7 |
Kawaguchi K, Yashima K, Murawaki Y. Tu1611 Usefulness of narrow band imaging with magnifying endoscopy for detection of primary and second primary esophageal cancer in patients with head and neck cancer, esophageal cancer, or gastric cancer［J］. Gastrointestinal Endoscopy, 2012, 75（4）：AB464-AB464.
|
| 8 |
Tara S, Bhatnagar V, Dwivedi D, et al. Narrow-band imaging with magnifying endoscopy for the screening of esophageal cancer in patients with primary head and neck cancers［J］. Endoscopy, 2010,42（08）：613-619.
|
| 9 |
Goda K, Dobashi A, Yoshimura N, et al. Narrow-band imaging magnifying endoscopy versus lugol chromoendoscopy with pink-color sign assessment in the diagnosis of superficial esophageal squamous neoplasms： a randomised noninferiority trial［J］. Gastroenterol Res Pract, 2015, 2015： 639462
|
| 10 |
张志宏，李良平，刘晓岗，等.不同内镜方式判断早期食管癌浸润深度准确性的对比研究［J］.中华消化内镜杂志，2017，34（1）：43-48.
|
| 11 |
胡冬梅，汤琪云，薛成俊，等.不同内镜检查方式对早期食管癌浸润深度的评估价值［J］.贵州医科大学学报，2018，43（1）：110-113.
|
| 12 |
袁慧敏.白光内镜、窄带成像放大内镜及超声内镜判断食管癌早癌浸润深度的对比研究［J］.哈尔滨医药,2021,41（3）：95-96.
|
| 13 |
魏书堂,徐菱遥,杨丙信，等.超声内镜检查联合放大内镜结合窄带成像检查对早期食管癌及其浸润深度的诊断价值［J］.癌症进展,2023,21（22）：2485-2487，2503.
|
| 14 |
郭权. N-乙酰半胱氨酸缓解Lugol's 碘染色引起的食管不适症状的研究［D］. 导师：刘志国. 中国人民解放军空军军医大学, 2023.
|
| 15 |
郑雅琪,黄海花,许秀娥,等.食管鳞癌及癌前病变分子标志物的发现及联合诊断模型效能验证的研究［C］//中国抗癌协会肿瘤标志专业委员会,中国抗癌协会整合肿瘤学分会.2022CCTB 中国肿瘤标志物学术大会暨中国整合肿瘤学大会暨第十六届肿瘤标志物青年科学家论坛暨中国肿瘤标志物产业创新大会论文集.汕头大学医学院；汕头大学医学院第二附属医院；黑龙江工程学院；
|
| 16 |
李国仁. 精准医学时代我国食管癌筛查和早期诊断的研究进展［J/OL］. 中华胸部外科电子杂志, 2020, 7（2）：7.
|
| 17 |
Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortalityin China, 2013［J］. Cancer Lett, 2017, 401： 63-71.
|
| 18 |
Wang GQ, Wei WW. A new transition of the screening, early diagnosis and early treatment project of the upper gastrointestinal cancer：opportunistic screening［J］. Zhonghua Yu Fang Yi Xue Za Zhi, 2019 Nov 6；53（11）：1084-1087.
|
| 19 |
Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage i esophageal squamous cell carcinoma［J］. Gastroenterology, 2019, 157（2）：382-390.e3.
|
| 20 |
Yang Y, Su Y, Zhang X, et al. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection： study protocol for a multicenter randomized controlled trial （Ad-ESD Trial）［J］. Trials, 2020, 21（1）：603.
|
| 21 |
Li B, Xiang J, Zhang Y, et al. Comparison of Ivor-Lewis vs sweet esophagectomy for esophageal squamous cell carcinoma： a randomized clinical trial［J］. JAMA Surg, 2015 150（4）： 292-298.
|
| 22 |
Li B, Hu H, Zhang Y, et al. Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma： three-year survival of a prospective, randomized, open-label trial［J］. Ann Surg, 2018,267（5）：826-832.
|
| 23 |
Ye T, Sun Y, Zhang Y, et al. Three-field or two-field resection for thoracic esophageal cancer： a meta-analysis［J］. Ann Thorac Surg,2013, 96（6）：1933-1941.
|
| 24 |
Li B, Zhang Y, Miao L, et al. Esophagectomy with three-field versus two-field lymphadenectomy for middle and lower thoracic esophageal cancer： long-term outcomes of a randomized clinical trial［J］. J Thorac Oncol, 2021, 16（2）： 310-317.
|
| 25 |
Liu F, Yang W, Yang W, et al. Minimally invasive or open esophagectomy for treatment of resectable esophageal squamous cell carcinoma？ Answer from a real-world multicenter study［J］. Ann Surg,2023, 277（4）：e777-e784.
|
| 26 |
Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma［J］. N Engl J Med,2022, 386（5）： 449-462.
|
| 27 |
Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus［J］. N Engl J Med, 1992, 326（24）：1593-1598.
|
| 28 |
Li C, Wang X, Wang L, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China： the multi-center 3JECROG survey［J］. Acta Oncol, 2021, 60（5）： 627-634.
|
| 29 |
Wang L, Liu L, Cao Y, et al. Simultaneous integrated boost intensitymodulated radiotherapy （SIB-IMRT） combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma （ESCC）： a phase Ⅱ clinical trial［J］. BMC Cancer, 2024, 24（1）： 679.
|
| 30 |
Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer： a retrospective,single-institutional analysis［J］. Int J Radiat Oncol Biol Phys, 2017,99（3）： 667-676.
|
| 31 |
Hirano Y, Onozawa M, Hojo H, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma［J］. Radiat Oncol, 2018, 13（1）：23.
|
| 32 |
Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis［J］. J Radiat Res,2015,56（3）：568-576.
|
| 33 |
Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer［J］ .J Clin Oncol,2020,38（14）：1569-1579.
|
| 34 |
Lertbutsayanukul C, Kitpanit S, Kannarunimit D, et al. High-dose Intensity-modulated proton therapy versus standard-dose intensitymodulated radiation therapy for esophageal squamous cell carcinoma（HI-SIRI）： study protocol for a randomized controlled clinical trial［J］.Trials, 2022, 23（1）： 897.
|